(Bloomberg) A Chinese maker of drugs used in cancer treatments surged in Hong Kong after an initial public offering priced at the top of a marketed range, a rare case of strong demand for a listing in the financial hub this year.Most Read from BloombergAston Martin Owner Lawrence Stroll Sells F1 Team Stake at £1 Billion ValuationHamas Mastermind Who Tricked Israel Is Top Target in Gaza TunnelsApple Plans to Make It Easier to Text Between iPhones and Androids‘Fed-Friendly’ Data Lift Bonds as S
(Bloomberg) Japanese initial public offerings may keep luring buyers after having delivered the biggest gains among newly listed Asian shares this year in the world’s best-performing equity market.Most Read from BloombergNYC Air Quality Drops to Unhealthy Levels — But Canadian Fires Aren’t to BlameXi’s Metal Curbs Risk Backfiring as G-7 Seeks China AlternativeBond Yields Higher as Another Rate Hike Signaled: Markets WrapEarth Keeps Breaking Temperature Records Due to Global WarmingFed Minutes
Top Asia IPO Gainers Are in Japan as Nation Lures Global Funds bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.
Chinese spirit maker ZJLD Group's shares ended down 18% on their first day of trading on Thursday, dampening hopes that a positive debut for the largest new share sale in Hong Kong in 2023 could spark a rush of listings in the second half.